| Title |
Hormone therapy in postmenopausal women and risk of endometrial hyperplasia
|
|---|---|
| Published in |
Cochrane database of systematic reviews, August 2012
|
| DOI | 10.1002/14651858.cd000402.pub4 |
| Pubmed ID | |
| Authors |
Susan Furness, Helen Roberts, Jane Marjoribanks, Anne Lethaby |
| Abstract |
Reduced circulating estrogen levels around the time of the menopause can induce unacceptable symptoms that affect the health and well-being of women. Hormone therapy (both unopposed estrogen and estrogen/progestogen combinations) is an effective treatment for these symptoms, but is associated with risk of harms. Guidelines recommend that hormone therapy be given at the lowest effective dose and treatment should be reviewed regularly. The aim of this review is to identify the minimum dose(s) of progestogen required to be added to estrogen so that the rate of endometrial hyperplasia is not increased compared to placebo. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 1 | 25% |
| United States | 1 | 25% |
| Unknown | 2 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 247 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 2 | <1% |
| France | 1 | <1% |
| Ireland | 1 | <1% |
| Unknown | 243 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 31 | 13% |
| Student > Bachelor | 31 | 13% |
| Student > Master | 30 | 12% |
| Student > Ph. D. Student | 28 | 11% |
| Other | 14 | 6% |
| Other | 44 | 18% |
| Unknown | 69 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 101 | 41% |
| Nursing and Health Professions | 17 | 7% |
| Psychology | 11 | 4% |
| Agricultural and Biological Sciences | 10 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 3% |
| Other | 23 | 9% |
| Unknown | 77 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 December 2017.
All research outputs
#2,588,454
of 25,838,141 outputs
Outputs from Cochrane database of systematic reviews
#5,090
of 13,141 outputs
Outputs of similar age
#16,659
of 186,914 outputs
Outputs of similar age from Cochrane database of systematic reviews
#81
of 212 outputs
Altmetric has tracked 25,838,141 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,141 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.2. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 186,914 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 212 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.